(INCY)—IMV.TO +36% last week on these data: https://globenewswire.com/news-release/2017/12/05/1229000/0/en/Immunovaccine-Announces-Positive-Clinical-Data-from-Its-Collaborative-Combination-Immunotherapy-Trial-in-Advanced-Ovarian-Cancer.html The collaboration with INCY is only for conducting the phase-1b trial. There was a CC on 12/5/17.